Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 20/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18626463 | 0.92 | MME (0.53) | MME | |
| SCHEMBL18874827 | 0.92 | MME (0.52) | MMEACE | |
| SCHEMBL16939262 | 0.92 | MME (0.52) | MMEACE | |
| SCHEMBL18874867 | 0.91 | MME (0.57) | MMEACE | |
| SCHEMBL16939261 | 0.86 | MME (0.55) | MMEACE | |
| SCHEMBL16939310 | 0.86 | MME (0.51) | MMEACE | |
| SCHEMBL20099595 | 0.86 | MME (0.56) | MMEACE | |
| SCHEMBL18626436 | 0.86 | MME (0.54) | MMEACE | |
| SCHEMBL16939300 | 0.85 | MME (0.51) | MMEACE | |
| SCHEMBL18626466 | 0.85 | MME (0.55) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | MME 1/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.